drugset / Trial / NCT04667897
601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)
RandomizedParallel-groupTriple-blindTreatment
Summary
To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to macular edema secondary to BRVO
Timeline
- Start
- 2021-01-28
- Primary completion
- 2022-07-13
- Completion
- 2022-07-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 601 | Monoclonal antibody | 1.25 mg | Intravitreal |
| Subject | Ranibizuman | Unknown | 0.5 mg | Intravitreal |